CrossBridge Bio, a Houston-based biotechnology company founded in 2023, has raised $10 million in seed financing, led by TMC Venture Fund and CE-Ventures, along with support from Portal Innovations, Alexandria Venture Investments, and Linden Lake Labs. The funding will advance the development of its lead program for treating solid tumors and expand its pipeline. Dr. Michael Torres, CEO, expressed enthusiasm for the backing from experienced investors. Additionally, William McKeon and Dr. Damir Illich will join the company’s board of directors as part of this financing effort.